Andrew Gottesdiener focuses on healthcare investments in Venrock’s New York office. Prior to joining Venrock, Andrew earned his MD at Weill Cornell Medical College during which he received an HHMI summer fellowship for basic science research. He also has an MBA from Columbia Business School where he graduated with Dean’s Honors and Distinction. Prior to medical school, Andrew worked in the Appel Alzheimer’s Disease Research Institute at Weill Cornell where he was developing preclinical gene therapy platforms to treat Alzheimer’s disease.
Andrew earned his AB in Economics from Washington University in St. Louis, where he graduated with College Honors and spent three years in the lab of Dr. David Holtzman studying the mechanisms of Alzheimer’s disease pathogenesis.